{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:41:42Z","timestamp":1790800902738,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) treatment options have evolved rapidly, but how new agents are incorporated into treatment decisions in current practice is not well understood. This study examined prescribing trends of physicians treating newly diagnosed MM and treatment outcomes in the United States. Electronic health record data from 6271 adult patients diagnosed with MM and receiving initial treatment between 1\u00a0January 2011 and 31\u00a0January 2020 were derived from the Flatiron Health electronic\u2010health record de\u2010identified database. The number\/types of agents included in therapy regimens, time to next treatment (TTNT), and overall survival (OS) were assessed. Subgroups were analyzed by the International Staging System (ISS) disease stage at diagnosis, stem cell transplant eligibility and timing, and practice type. Exploratory prognostic models evaluated the association between baseline covariates and time\u2010to\u2010event outcomes. The proportion of patients receiving triplet therapies increased from 2011 (36%) to 2019 (72%) as those receiving initial monotherapy or doublet therapy decreased. Overall, the most prevalent triplet regimen consisted of an immunomodulatory drug (IMiD), a proteasome inhibitor, and a steroid. From 2017 to 2019, median TTNT from front\u2010line to second\u2010line was longer in patients with ISS stage I versus stages II\/III, and in those receiving IMiD\u2010containing doublet or triplet therapies versus other combinations. Overall median OS was 56\u00a0months and increased from 2011 to 2014, after which median OS was not yet reached. Age, ISS stage, and high\u2010risk status were prognostic for both OS and TTNT, while sex, practice type, and ECOG status were prognostic for OS only.<\/jats:p>","DOI":"10.1002\/cam4.4137","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T05:24:20Z","timestamp":1629177860000},"page":"5866-5877","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Front\u2010line treatment patterns in multiple myeloma: An analysis of U.S.\u2010based electronic health records from 2011 to 2019"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"first","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellissa","family":"Williamson","sequence":"additional","affiliation":[{"name":"Genentech, Inc. South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzor","family":"Ogbu","sequence":"additional","affiliation":[{"name":"Genentech, Inc. South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Surinach","sequence":"additional","affiliation":[{"name":"Genesis Research Hoboken NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Arndorfer","sequence":"additional","affiliation":[{"name":"Genesis Research Hoboken NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan\u2010Jen","family":"Hong","sequence":"additional","affiliation":[{"name":"Genentech, Inc. South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8039"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy073"},{"key":"e_1_2_10_4_1","unstructured":"National Cancer Institute: Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Myeloma.https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed 14 June 2020."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.145078"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016002493"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.11.007"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0023"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.518"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.5776.5776"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1105202"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3558.3558"},{"issue":"1","key":"e_1_2_10_14_1","article-title":"Real\u2010world treatment outcomes in patients with newly diagnosed multiple myeloma treated with triplet therapy without stem cell transplant: an enhanced electronic health records database [abstract]","volume":"130","author":"Chari A","year":"2017","journal-title":"Blood"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"issue":"5","key":"e_1_2_10_18_1","first-page":"53","article-title":"Longer term follow\u2010up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood","volume":"10","author":"Durie BGM","year":"2020","journal-title":"Cancer J"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2656"},{"key":"e_1_2_10_23_1","unstructured":"Connect MM Registry.https:\/\/celgeneregistry.com\/public\/mm. Accessed 23 July 2020."},{"key":"e_1_2_10_24_1","unstructured":"National Cancer Institute DoCCaPS.Surveillance Epidemiology and End Results (SEER).https:\/\/seer.cancer.gov\/about\/factsheets\/SEER_Overview.pdf. Accessed 23 July 2020."},{"key":"e_1_2_10_25_1","unstructured":"American College of Surgeons.National Cancer Database.https:\/\/www.facs.org\/quality\u2010programs\/cancer\/ncdb. Accessed 23 July 2020."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0163-7"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.10.002"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.07.005"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2264(199706)19:2<124::AID-GCC8>3.0.CO;2-0"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4137","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4137","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T17:09:02Z","timestamp":1693328942000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":28,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1002\/cam4.4137"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4137","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"2021-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}